- Home
- ADI vs BMY Comparison
ADI vs BMY Comparison
Compare ADI & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADI
- BMY
- Stock Information
- Founded
- ADI 1965
- BMY 1887
- Country
- ADI United States
- BMY United States
- Employees
- ADI N/A
- BMY N/A
- Industry
- ADI Semiconductors
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- ADI Technology
- BMY Health Care
- Exchange
- ADI Nasdaq
- BMY Nasdaq
- Market Cap
- ADI 105.1B
- BMY 115.3B
- IPO Year
- ADI 1972
- BMY N/A
- Fundamental
- Price
- ADI $238.91
- BMY $55.84
- Analyst Decision
- ADI Buy
- BMY Hold
- Analyst Count
- ADI 23
- BMY 14
- Target Price
- ADI $253.59
- BMY $58.00
- AVG Volume (30 Days)
- ADI 4.2M
- BMY 11.5M
- Earning Date
- ADI 02-19-2025
- BMY 02-06-2025
- Dividend Yield
- ADI 1.66%
- BMY 4.44%
- EPS Growth
- ADI N/A
- BMY N/A
- EPS
- ADI 3.13
- BMY N/A
- Revenue
- ADI $9,337,627,000.00
- BMY $48,300,000,000.00
- Revenue This Year
- ADI $8.92
- BMY N/A
- Revenue Next Year
- ADI $13.56
- BMY N/A
- P/E Ratio
- ADI $76.14
- BMY N/A
- Revenue Growth
- ADI N/A
- BMY 7.32
- 52 Week Low
- ADI $182.57
- BMY $39.35
- 52 Week High
- ADI $247.10
- BMY $61.10
- Technical
- Relative Strength Index (RSI)
- ADI 68.52
- BMY 45.21
- Support Level
- ADI $200.80
- BMY $53.54
- Resistance Level
- ADI $247.10
- BMY $56.54
- Average True Range (ATR)
- ADI 6.15
- BMY 1.41
- MACD
- ADI 4.17
- BMY -0.26
- Stochastic Oscillator
- ADI 82.31
- BMY 33.72
About ADI Analog Devices Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.